Stock of the Day

February 4, 2025

CVS Health (CVS)

$92.45
+$2.06 (+2.3%)
Market Cap: $115.61B

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

CVS Health Bull Case

Here are some ways that investors could benefit from investing in CVS Health Co.:

  • CVS Health Co. recently reported strong third-quarter earnings, beating analyst expectations with an actual earnings per share of $2.58 compared to the consensus estimate of $1.87, demonstrating the company's ability to outperform market forecasts and drive shareholder value through operational efficiency.
  • The stock is currently trading at $87.93, which is significantly below the consensus price target of $107.24 set by Wall Street analysts, suggesting a potential upside of approximately 22% for investors who believe the market is currently undervaluing the company's turnaround efforts.
  • CVS Health Co. has raised its full-year 2026 earnings per share guidance to a range of $7.90 to $8.10, which is well above the previous consensus estimate of $7.44, indicating management's confidence in sustained revenue growth and cost management throughout the remainder of the fiscal year.
  • The company offers a dividend yield of 3.03%, providing a steady income stream for investors, which is particularly attractive given the stock's recent volatility and its position near the lower end of its 52-week trading range between $69.51 and $110.68.
  • Recent institutional activity shows positive momentum, with firms like Farther Finance Advisors LLC increasing their holdings by 30.6% in the third quarter, signaling that professional investors are accumulating shares and potentially identifying a long-term value opportunity in the healthcare sector.

CVS Health Bear Case

Investors should be bearish about investing in CVS Health Co. for these reasons:

  • CVS Health Co. faces significant regulatory and reputational risk following the initiation of an investigation by Kahn Swick & Foti, LLC into the company's officers and directors, which could lead to legal costs, management distraction, and potential financial liabilities that are not yet reflected in the current stock price.
  • The company's Aetna unit received weaker-than-expected Medicare Advantage star ratings for 2027, with TD Cowen estimating this could result in a $0.41 hit to earnings per share, highlighting ongoing challenges in maintaining high-quality clinical performance and member satisfaction in a competitive insurance market.
  • Despite recent earnings beats, the stock has experienced a sharp retreat from its summer highs, with a gap down of 10.7% observed in August 2026, suggesting that investors may be pricing in structural headwinds such as increasing medical costs and reimbursement pressures that could limit future profitability.
  • CVS Health Co. carries a debt-to-equity ratio of 0.74 and a current ratio of 0.87, indicating that the company has more short-term liabilities than current assets, which could constrain its financial flexibility and ability to invest in growth initiatives during periods of economic uncertainty.
  • Recent insider selling activity, including large block sales by Director Larry Robbins in May 2026, may signal a lack of confidence among company insiders regarding the stock's near-term valuation, potentially dampening retail investor sentiment and limiting upward price momentum.

3 Dividend Stocks at Bargain Levels to Defend Your Portfolio

Written By Ryan Hasson on 1/15/2025

A bag of money with the word dividends written on it, on a dollar background.

As 2025 kicks off with a volatile start, many investors are likely feeling the pressure of heightened uncertainty. The S&P 500 and other major indices are down year-to-date, led by sharp declines in tech heavyweights like NVIDIA, which has fallen 13% from its 52-week high set just days ago. Market sentiment has been further dampened by a hot December jobs report, reigniting fears of prolonged higher interest rates.

For cautious investors looking to safeguard their portfolios, high-yielding dividend stocks trading near fair value could offer income and stability in these turbulent times.

Let’s take a closer look at three contenders, each presenting attractive valuations based on their P/E, technical positioning, and strong yields.

Devon Energy Breaks Its Long-Term Downtrend

The energy sector has started 2025 on a strong note, with the popular Energy Select Sector SPDR Fund ETF (NYSEARCA: XLE) up 5.36% year-to-date, making it the top-performing sector YTD. Devon Energy (NYSE: DVN) has been a standout within this space, surging over 12% this year.

As one of the U.S.'s largest independent oil and gas producers, Devon operates in highly productive regions like the Delaware Basin.

Devon’s dividend yield is especially attractive, combining a fixed and variable component tied to free cash flow. While its forward yield stands at 4.13%, it could rise significantly if oil prices continue to climb. After spending much of 2024 in decline, Devon recently broke out of a long-term downtrend, clearing a critical resistance level.

This technical shift suggests further upside if the stock establishes a base above its breakout zone. 

Analysts are bullish, with a Moderate Buy rating and a price target of $49.43, offering additional upside potential.

CVS Health Stands Out as Early Outperformer in 2025

CVS Health Corp. (NYSE: CVS), a dominant player in the U.S. healthcare industry, is best known for its CVS Pharmacy locations, CVS Caremark, and Aetna health plans. The company faced significant challenges in 2024, including lower demand for COVID-related products and rising costs tied to its booming Medicare Advantage (MA) plans.

These headwinds caused the stock to underperform, but the narrative is beginning to shift. A recent government proposal to increase MA payments in 2026 has renewed optimism, helping shares climb nearly 15% year-to-date as of Monday's close, defying the broader market’s slump.

On the technical side, CVS has broken out of a consolidation base near $45 and is now approaching its 50-day simple moving average, signaling strengthening momentum. CVS offers an impressive 5.16% dividend yield for income-focused investors, paired with an attractive P/E ratio of 13.08.

Analysts are optimistic, maintaining a Moderate Buy rating and projecting a nearly 33% upside to the consensus price target. As a defensive healthcare leader with improving prospects, CVS could be a compelling choice for yield and value investors.

Ford Motor Co. Enters Potential Deep Value Territory

Ford Motor Co. (NYSE: F), an icon in the automotive sector, has recently faced its share of challenges. Over the past year, the stock has fallen nearly 16%, weighed down by rising recall and warranty costs and continued losses in its electric vehicle (EV) segment.

However, management has signaled a turning point, projecting better EV margins by 2025 through cost improvements.

Valuation metrics highlight Ford’s appeal to bargain hunters, with a P/E of 11.07 and a forward P/E of just 5.74. For income seekers, Ford’s 6.18% dividend yield is particularly enticing. Technically, the stock has established a support zone near $9.50, which could act as a double-bottom if the stock takes out near-term resistance near $10.

Analysts are lukewarm on Ford, though, assigning a Reduce rating, but the consensus price target of $11.83 still implies an impressive upside from current levels. Ford might be worth considering for investors seeking a high-yielding stock with potential value as it navigates its cost-cutting turnaround strategy.

Recent News